The disclosure relates to A combination of : (i) component A, which is a compound represented by structural formula shown herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof； (ii) component B, which is (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof； and, optionally, (iii) component C : one or more further pharmaceutical agents； in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially, dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route. These combinations are suitable for the treatment or prophylaxis of a cancer selected from hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer or breast cancer. Also disclosed is a kit comprising such a combination, which is adapted for actually making a pharmaceutical formulation which is to be used as a combination therapy for treating cancer.
